| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CERo Therapeutics Holdings, Inc., (OTC:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy co...
Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs (NASDAQ:CERO) from Buy to Hold.
CERo Therapeutics Holdings, Inc. (OTC:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy com...
D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs (NASDAQ:CERO) with a Buy and maintains $30 price ta...